Depletion of Acetyl-CoA Carboxylase 1 Facilitates Epithelial-Mesenchymal Transition in Prostate Cancer Cells by Activating the MAPK/ERK Pathway

Abstract

Hyperactivation of fatty acid biosynthesis holds promise as a targeted therapeutic strategy in prostate cancer (PCa). However, inhibiting these enzymes could potentially promote metastatic progression in various other cancers. Herein, we found that depletion of acetyl-CoA carboxylase 1 (encoded by ACACA), the enzyme responsible for the first and rate-limiting step of de novo fatty acid biosynthesis, facilitated epithelial-mesenchymal transition (EMT) and migration of PCa cells. This finding was validated in vitro through cell migration assays and in vivo using a metastatic model established by tail vein injection of ACACA-depleted cells into BALB/c nude mice. Additionally, depletion of ACACA activated the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated protein kinases (ERK) pathway. Inhibition of the MAPK/ERK signaling pathway reduced EMT and migration in ACACA-depleted cells. Our study is the first to indicate targeting ACACA induces an “unexpected” escape program through activation of the MAPK/ERK signaling pathway in PCa, ultimately leading to EMT and metastasis. Therefore, we strongly recommend that the potential adverse effects of targeting ACACA or its derived therapeutic agents must be given extreme attention, especially in MAPK-related cancers.

Keywords

ACACA / EMT / fatty acid biosynthesis / MAPK / metastasis / prostate cancer

References

[1] L. A. Sena and S. R. Denmeade, “Fatty Acid Synthesis in Prostate Cancer: Vulnerability or Epiphenomenon?,” Cancer Research 81, no. 17 (2021): 4385–4393.

[2] C. Spick, K. Herrmann, and J. Czernin, “Evaluation of Prostate Cancer With 11C-Acetate PET/CT,” Journal of Nuclear Medicine 57, no. S3 (2016): 30S–37S.

[3] H. Zhang, S. Liu, Z. Cai, et al., “Down-Regulation of ACACA Suppresses the Malignant Progression of Prostate Cancer Through Inhibiting Mitochondrial Potential,” Journal of Cancer 12, no. 1 (2021): 232–243.

[4] S. Liu, J. Lai, Y. Feng, et al., “Acetyl-CoA Carboxylase 1 Depletion Suppresses De Novo Fatty Acid Synthesis and Mitochondrial β-Oxidation in Castration-Resistant Prostate Cancer Cells,” Journal of Biological Chemistry 299, no. 1 (2023): 102720.

[5] D. Hanahan and R. A. Weinberg, “Hallmarks of Cancer: The Next Generation,” Cell 144, no. 5 (2011): 646–674.

[6] J. Yang, P. Antin, G. Berx, et al., “Guidelines and Definitions for Research on Epithelial-Mesenchymal Transition,” Nature Reviews Molecular Cell Biology 21, no. 6 (2020): 341–352.

[7] Y. Huang, W. Hong, and X. Wei, “The Molecular Mechanisms and Therapeutic Strategies of EMT in Tumor Progression and Metastasis,” Journal of Hematology & Oncology 15, no. 1 (2022): 129.

[8] C. Abate-Shen, “Prostate Cancer Metastasis—Fueled by Fat?,” New England Journal of Medicine 378, no. 17 (2018): 1643–1645.

[9] M. Chen, J. Zhang, K. Sampieri, et al., “An Aberrant SREBP-Dependent Lipogenic Program Promotes Metastatic Prostate Cancer,” Nature Genetics 50, no. 2 (2018): 206–218.

[10] H. Lavoie, J. Gagnon, and M. Therrien, “ERK Signalling: A Master Regulator of Cell Behaviour, Life and Fate,” Nature Reviews Molecular Cell Biology 21, no. 10 (2020): 607–632.

[11] H. Chen, G. Zhu, Y. Li, et al., “Extracellular Signal-Regulated Kinase Signaling Pathway Regulates Breast Cancer Cell Migration by Maintaining Slug Expression,” Cancer Research 69, no. 24 (2009): 9228–9235.

[12] C. Choi and D. M. Helfman, “The Ras-ERK Pathway Modulates Cytoskeleton Organization, Cell Motility and Lung Metastasis Signature Genes in MDA-MB-231 LM2,” Oncogene 33, no. 28 (2014): 3668–3676.

[13] A. A. Brahmbhatt and R. L. Klemke, “ERK and RhoA Differentially Regulate Pseudopodia Growth and Retraction During Chemotaxis,” Journal of Biological Chemistry 278, no. 15 (2003): 13016–13025.

[14] M. E. Bahar, H. J. Kim, and D. R. Kim, “Targeting the RAS/RAF/MAPK Pathway for Cancer Therapy: From Mechanism to Clinical Studies,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 455.

[15] R. U. Svensson, S. J. Parker, L. J. Eichner, et al., “Inhibition of Acetyl-CoA Carboxylase Suppresses Fatty Acid Synthesis and Tumor Growth of Non-Small-Cell Lung Cancer in Preclinical Models,” Nature Medicine 22, no. 10 (2016): 1108–1119.

[16] J. S. V Lally, S. Ghoshal, D. K. DePeralta, et al., “Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma,” Cell Metabolism 29, no. 1 (2019): 174–182.e5.

[17] H. Ito, I. Nakamae, J. Y. Kato, et al., “Stabilization of Fatty Acid Synthesis Enzyme Acetyl-CoA Carboxylase 1 Suppresses Acute Myeloid Leukemia Development,” Journal of Clinical Investigation 131, no. 12 (2021): e141529.

[18] G. Falchook, J. Infante, H. T. Arkenau, et al., “First-In-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of First-In-class Fatty Acid Synthase Inhibitor TVB-2640 Alone and With a Taxane in Advanced Tumors,” EClinicalMedicine 34 (2021): 100797.

[19] W. Kelly, A. E. Diaz Duque, J. Michalek, et al., “Phase II Investigation of TVB-2640 (Denifanstat) With bevacizumab in Patients With First Relapse High-Grade Astrocytoma,” Clinical Cancer Research 29, no. 13 (2023): 2419–2425.

[20] Y. Fu, T. Zou, X. Shen, et al., “Lipid Metabolism in Cancer Progression and Therapeutic Strategies,” MedComm 2, no. 1 (2020): 27–59.

[21] M. Rios Garcia, B. Steinbauer, K. Srivastava, et al., “Acetyl-CoA Carboxylase 1-Dependent Protein Acetylation Controls Breast Cancer Metastasis and Recurrence,” Cell metabolism 26, no. 6 (2017): 842–855.e5.

[22] L. Jiang, L. Xiao, H. Sugiura, et al., “Metabolic Reprogramming During TGFβ1-Induced Epithelial-to-Mesenchymal Transition,” Oncogene 34, no. 30 (2015): 3908–3916.

[23] B. A. Carneiro and W. S. El-Deiry, “Targeting Apoptosis in Cancer Therapy,” Nature Reviews Clinical Oncology 17, no. 7 (2020): 395–417.

[24] E. G. Bluemn, I. M. Coleman, J. M. Lucas, et al., “Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained Through FGF Signaling,” Cancer Cell 32, no. 4 (2017): 474–489.e6.

[25] D. J. Mulholland, N. Kobayashi, M. Ruscetti, et al., “Pten Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated From Prostate Cancer Stem/Progenitor Cells,” Cancer Research 72, no. 7 (2012): 1878–1889.

[26] R. Ullah, Q. Yin, A. H. Snell, and L. Wan, “RAF-MEK-ERK Pathway in Cancer Evolution and Treatment,” Seminars in Cancer Biology 85 (2022): 123–154.

[27] C. W. Kinkade, M. Castillo-Martin, A. Puzio-Kuter, et al., “Targeting AKT/mTOR and ERK MAPK Signaling Inhibits Hormone-Refractory Prostate Cancer in a Preclinical Mouse Model,” Journal of Clinical Investigation 118, no. 9 (2008): 3051–3064.

[28] Q. Wu, Y. B. Wang, X. W. Che, et al., “Junctional Adhesion Molecule-Like Protein as a Novel Target for Kaempferol to Ameliorate Lung Adenocarcinoma,” Journal of Integrative Medicine 21, no. 3 (2023): 268–276.

[29] M. Scaltriti, L. Prudkin, et al., “PI3K Inhibition Results in Enhanced HER Signaling and Acquired ERK Dependency in HER2-Overexpressing Breast Cancer,” Oncogene 30, no. 22 (2011): 2547–2557.

[30] A. Carracedo, L. Ma, J. Teruya-Feldstein, et al., “Inhibition of mTORC1 Leads to MAPK Pathway Activation Through a PI3K-Dependent Feedback Loop in Human Cancer,” Journal of Clinical Investigation 118, no. 9 (2008): 3065–3074.

[31] Q. Li, Z. Li, T. Luo, et al., “Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK Pathways for Cancer Therapy,” Molecular Biomedicine 3 (2022): 47.

[32] M. C. Mendoza, E. E. Er, and J. Blenis, “The Ras-ERK and PI3K-mTOR Pathways: Cross-Talk and Compensation,” Trends in Biochemical Sciences 36, no. 6 (2011): 320–328.

[33] L. W. S Finley, “What Is Cancer Metabolism?,” Cell 186, no. 8 (2023): 1670–1688.

[34] F. C. E Vogel, A. B Chaves-Filho, and A. Schulze, “Lipids as Mediators of Cancer Progression and Metastasis,” Nature Cancer 5, no. 1 (2024): 16–29.

[35] A. Du, Z. Wang, T. Huang, et al., “Fatty Acids in Cancer: Metabolic Functions and Potential Treatment,” MedComm—Oncology 2 (2023): e25.

[36] J. Xu, S. Lamouille, and R. Derynck, “TGF-Beta-Induced Epithelial to Mesenchymal Transition,” Cell Research 19, no. 2 (2009): 156–172.

[37] P. Yang, C. Su, X. Luo, et al., “Dietary Oleic Acid-Induced CD36 Promotes Cervical Cancer Cell Growth and Metastasis via Up-Regulation Src/ERK Pathway,” Cancer Letters 438 (2018): 76–85.

[38] J. Liu, G. Chen, Z. Liu, et al., “Aberrant FGFR Tyrosine Kinase Signaling Enhances the Warburg Effect by Reprogramming LDH Isoform Expression and Activity in Prostate Cancer,” Cancer Research 78, no. 16 (2018): 4459–4470.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.